Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.
about
Focus on adoptive T cell transfer trials in melanomaAdoptive immunotherapy for cancer: building on successDurable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapySpecific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patientsAdoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimensAdoptive cell transfer: a clinical path to effective cancer immunotherapyTrial Watch: Adoptive cell transfer for oncological indicationsApplications of next-generation sequencing to blood and marrow transplantationSorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlookChimeric antigen receptor therapy for cancerT cell replicative senescence in human agingLineage relationship of effector and memory T cellsImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationTechnical Considerations for the Generation of Adoptively Transferred T Cells in Cancer ImmunotherapyT cell engineering as therapy for cancer and HIV: our synthetic futureSleeping beauty system to redirect T-cell specificity for human applications.Phase I clinical trial of fibronectin CH296-stimulated T cell therapy in patients with advanced cancer.Activation of tolerogenic dendritic cells in the tumor draining lymph nodes by CD8+ T cells engineered to express CD40 ligand.Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15IFN-γ upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells.Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation.Principles of adoptive T cell cancer therapy.Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanomaICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanomaEx vivo expansion of human CD8+ T cells using autologous CD4+ T cell helpTelomerase and primary T cells: biology and immortalization for adoptive immunotherapy.HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice.Th17 cells are long lived and retain a stem cell-like molecular signatureUse of tumour-responsive T cells as cancer treatment.CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.Human cell-based artificial antigen-presenting cells for cancer immunotherapy.Stem memory T cells (TSCM)-their role in cancer and HIV immunotherapiesHuman effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.Immunotherapy for ovarian cancer: what's next?
P2860
Q21328679-32CCA55E-B3E6-4300-A2D0-600C415E75CCQ24546258-E8E7B212-DDBC-4E57-B4E5-62C44975E930Q24596055-CC5267A6-6363-4826-BF1E-0798784DF202Q24598792-B7C64BEA-2C84-468C-B7F8-EC55DFAB1BAEQ24644442-247DA813-39B4-4BCE-B253-49AE17947837Q24644774-06CA3AD3-7A23-44FC-A19B-A882EC3267FDQ26785545-E041010E-9E2F-41C8-ABEE-48D0135D43C8Q26852890-965C99FB-0F53-4102-BBD5-29974D7AB503Q27002575-A43B6370-C755-4B9B-AC30-B99A08BD1B89Q27004178-C24B7B18-8D86-46B0-AD63-BCFD3BA88E22Q27013599-EDFEBA2E-D066-4543-BEAE-0086AD1CEDE5Q27022690-5632C7D3-FC32-4549-81C5-F0D4A004EF8FQ27026665-5655B8D0-4114-4443-B3BB-204C1CA4A543Q28068378-37B1E170-159C-4070-B1FC-488592FFEF51Q28073563-5D32E2E3-2533-484A-B1BB-84315B4B8043Q28082253-8ECD5A12-B81D-4B64-841A-BDC374B505F6Q30535187-84167219-07EC-4D53-B6E3-6318E379F77EQ33413155-11F85929-FBC3-485E-97DB-093E63DAADBCQ33746583-89EC36C4-D40B-4A03-8619-C4D73DF4A302Q33749635-5BAADB1F-D37E-43C3-ACAA-BF841080CA10Q33761188-06C57D4D-05C1-483D-AF82-A01760E87E79Q33862876-22D08FBC-6C1D-429F-A702-F2F9D1A1D7D7Q33874986-4BFCB945-1059-4053-BAA5-F854B1EED1B5Q34003932-F8BC3B66-F776-431E-9887-557BB5F12D2CQ34034408-6DA63875-55D8-4758-90B7-CAB8C1C8A50CQ34047847-7E0CBA43-4503-4D44-A2CF-2C1BDE0E3785Q34073529-74C6EC60-B303-406F-BE57-3E2553049887Q34111789-381800AA-D087-4E09-9674-EDB7FDCB9432Q34141754-F7A6A66A-4B04-415A-BEFD-D7145A54018CQ34170012-55026BA7-0479-4E30-BBDB-B4021134B962Q34204696-5E3963C1-273C-485D-8C49-18B18B5617ACQ34241261-31ADE2BE-5E1C-47CD-A23D-5D9428053A0FQ34285656-8F0F4699-4F31-4E9E-8D20-AF087885A1B2Q34299986-B4E44D51-187F-4DE2-A0C2-4BBD4E123517Q34300883-D6C5DE21-A09A-4856-9DDF-4E167D711C82Q34391263-59DF3448-7060-4BD8-964C-7F58F91DB229Q34511615-4F8238D5-BFBD-43CB-B703-56F4B0430727Q34557953-636E7B66-46AA-4AA6-9C57-507F353CCE6FQ34656292-0520A43E-DB6E-4654-9C10-139413A89A77Q34743514-5AF44615-A17A-4B05-BBBF-56FC46C0E1AA
P2860
Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Telomere length of transferred ...... ceiving cell transfer therapy.
@ast
Telomere length of transferred ...... ceiving cell transfer therapy.
@en
Telomere length of transferred ...... ceiving cell transfer therapy.
@nl
type
label
Telomere length of transferred ...... ceiving cell transfer therapy.
@ast
Telomere length of transferred ...... ceiving cell transfer therapy.
@en
Telomere length of transferred ...... ceiving cell transfer therapy.
@nl
prefLabel
Telomere length of transferred ...... ceiving cell transfer therapy.
@ast
Telomere length of transferred ...... ceiving cell transfer therapy.
@en
Telomere length of transferred ...... ceiving cell transfer therapy.
@nl
P2093
P2860
P1476
Telomere length of transferred ...... eceiving cell transfer therapy
@en
P2093
Jianping Huang
Juhua Zhou
Paul F Robbins
Steven A Rosenberg
P2860
P304
P356
10.4049/JIMMUNOL.175.10.7046
P407
P577
2005-11-01T00:00:00Z